8例替加环素致低钙血症不良反应分析

doi:10.19803/j.1672-8629.2021.01.15

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (1): 77-79.
DOI: 10.19803/j.1672-8629.2021.01.15

8例替加环素致低钙血症不良反应分析

陶宏, 沈珠, 曹国文^*, 施爱明, 潘杰

苏州大学附属第二医院药剂科,江苏苏州 215004

收稿日期:2019-11-12 修回日期:2021-01-18 出版日期:2021-01-15 发布日期:2021-01-18
通讯作者: ^*曹国文,男,本科,副主任药师,临床药学。E-mail:sdfecaoguowen@sina.com
作者简介:陶宏,男,本科,主管药师,临床药学。

Eight Cases of Hypocalcemia Induced by Tigecycline

TAO Hong, SHEN Zhu, CAO Guowen^*, SHI Aiming, PAN Jie

Department of Pharmacy,the Second Affiliated Hospital of Soochow University,Suzhou Jiangsu 215004,China

Received:2019-11-12 Revised:2021-01-18 Online:2021-01-15 Published:2021-01-18

摘要/Abstract

摘要： 目的提高临床使用替加环素的安全性。方法借助于某三甲医院2018年7月1日至2019年6月30日不良反应主动监测软件筛选使用替加环素发生低钙血症的患者,结合电子病历和药品不良反应判定标准对数据进行分析。结果使用替加环素与发生低钙血症相关。结论建议临床使用替加环素时,应加强对血钙的监测。

关键词: 替加环素, 低钙血症, 药品不良反应

Abstract: Objective To improve the safety of clinical use of tigecycline.Methods Patients with hypocalcemia caused by tigecycline were screened from July 1,2018 to June 30,2019 with active monitoring software for adverse reactions before data was analyzed using electronic medical records and adverse reaction criteria.Results The use of tigecycline was associated with hypocalcemia.Conclusion It is recommended that the monitoring of serum calcium be enhanced when tigecycline is used in clinic.

Key words: tigecycline, hypocalcemia, adverse drug reaction

中图分类号:

R994.11

陶宏, 沈珠, 曹国文, 施爱明, 潘杰. 8例替加环素致低钙血症不良反应分析[J]. 中国药物警戒, 2021, 18(1): 77-79.

TAO Hong, SHEN Zhu, CAO Guowen, SHI Aiming, PAN Jie. Eight Cases of Hypocalcemia Induced by Tigecycline[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 77-79.

参考文献

[1] Wenzel R,Bate G,Kirkpatrick P.Tigecycline[J].Nat Rev Drug Discov,2005,4(10):809-810.
[2] Bergeron J,Ammirati M,Danley D,et al.Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection[J].Antimicrob Agents Chemother,1996,40(9):2226-2228.
[3] Hu F,Guo Y,Yang Y,et al.Resistance reported from China antim-icrobial surveillance network (CHINET) in 2018[J].Eur J Clin Microbiol Infect Dis,2019,38(12):2275-2281.
[4] Kaewpoowat Q,Ostrosky-Zeichner L.Tigecycline :a critical safety review[J].Expert Opin Drug Saf,2015,14(2):335-342.
[5] Yamashita N,Matschke K,Gandhi A,et al.Tigecycline pharmacokinetics,tolerability,safety,and effect on intestinal microflora in healthy Japanese male subjects[J].J Clin Pharmacol,2014,54(5):513-519.
[6] Chen XX,Zhou XF,Quan QX,et al.Adverse reaction monitoring of patients with multi-drug resistant bacteria infection treated by tigecycline in ICU[J].Journal of Nursing(China)(护理学报),2012,19(11A):59-61.
[7] Jiang YN,Zhao ZG.Prevention and treatment of tumor lysis syndrome[J].J Clin Intern Med(临床内科杂志),2018,35(9):593-595.
[8] Riley MM.The rising problem of multidrug-resistant organisms in intensive care units[J].Crit Care Nurse,2019,39(4):48-55.
[9] He H,Zheng Y,Sun B,et al.Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii[J].J Thorac Dis,2016,8(10):2784-2792.
[10] Xu Y,Jin L,Liu N,et al.Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit[J].Int J Infect Dis,2019(82):79-85.
[11] Corsonello A,Abbatecola AM,Fusco S,et al.The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly[J].Clin Microbiol Infect,2015,21(1):20-26.
[12] De Pascale G,Montini L,Pennisi M,et al.High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria[J].Crit Care,2014,18(3):R90.
[13] Ramirez J,Dartois N,Gandjini H,et al.Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia[J].Antimicrob Agents Chemother,2013,57(4):1756-1762.
[14] de Brito Galvo JF,Schenck PA,Chew DJ.A quick reference on hypocalcemia[J].Vet Clin North Am Small Anim Pract,2017,47(2):249-256.
[15] Wang FF,Chen WH,He ZQ,et al.Analysis of literature and clinical cases of adverse drug reactions induced by zoledronic acid injection[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(4):223-227.

8例替加环素致低钙血症不良反应分析

Eight Cases of Hypocalcemia Induced by Tigecycline

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.